ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab. The primary outcome is relapse, while the secondary outcomes are disability status and adverse events. Results Twenty–two patients received ofatumumab for a median duration of 19.5 months (range 6–41). Among them, 18 patients (81.82%) remained relapse–free during follow–up. Annualized relapse rate (ARR) significantly decreased from 1.30 (95% CI 0.74–2.29) pretreatment to 0.12 (95% CI 0.04–0.35) during ofatumumab therapy (IRR 10.86, 95% CI 3.22–36.70, p < 0.001). Through propensity score matching, 11 patients in the ofatumumab group and 11 patients in the rituximab group were compared. Ofatumumab was observed to be associated with a significantly lower risk of a second attack (HR 0.233, 95% CI 0.061 to 0.893, p = 0.018) compared to rituximab. Adverse events were reported in 54.55% patients (6/11) treated with ofatumumab, most of which were mild and occurred after the initial dose. Interpretation Ofatumumab was associated with a lower relapse risk compared with rituximab in patients with MOGAD.
Fan et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: